<DOC>
	<DOC>NCT02211911</DOC>
	<brief_summary>To investigate if bisacodyl (Dulcolax®) and sodium picosulfate (Laxoberal®) is excreted in breast milk of healthy lactating women after an oral administration of 10 mg once daily over a period of 8 days.</brief_summary>
	<brief_title>Pharmacokinetics of Bisacodyl or Sodium Picosulfate Administered Orally in Healthy Lactating Females</brief_title>
	<detailed_description />
	<mesh_term>Bisacodyl</mesh_term>
	<mesh_term>Picosulfate sodium</mesh_term>
	<criteria>Women, age ≥18 and ≤50 years Stopped with breast feeding their baby Provided breast milk samples over a period of 10 days (including day 1) Have been breast feeding for at least 14 days Complied with the requirements of the protocol (e.g complete a diary) Body Mass Index (BMI) ≤ 35 kg/m2 Medically acceptable method of contraception [i.e., double barrier method (e.g., diaphragm or condom and spermicide), hormonal therapy (subcutaneous, injectable, intravaginal, or oral contraceptive) or intrauterine device Signed and dated a written informed consent prior to any study procedures study in accordance with Good Clinical practice (GCP) and the local legislation Findings during medical examination (including BP, pulse rate and ECG) deviating from normal and of clinical relevance Evidence of clinically relevant concomitant diseases like renal insufficiency, cardiac insufficiency, myocardial infarction, other known cardiovascular disease including hypertension Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorders, that may interfere with the safety of the subject Surgery of the gastrointestinal tract (except appendectomy) in the last 2 years Metabolic disorders, neurological disorders, severe or psychiatric disorders, or any other significant disease or intercurrent illness (e.g. abdominal/gastrointestinal surgery) that would interfere with participation in the study History of relevant orthostatic hypotension, fainting spells or blackouts Chronic or relevant acute infections (e.g. HIV, Hepatitis) Participated in another study with an investigational product within 1 month prior to enrolment into this study or during the study Eating disorder Hypersensitivity to bisacodyl, sodium picosulfate or any of the inactive ingredients Any concomitant medication except for paracetamol or hormonal therapy. Abnormal electrolyte values at the screening visit. The electrolyte values should be within the normal ranges Alcohol abuse; subjects who report regular consumption of 40g/day = 5 units/day or more alcoholic drinks per day were excluded Smoker (&gt;10 cigarettes or &gt; 3 cigars or &gt; 3 pipes/day) Drug abuse Any laboratory value outside the reference range that is of clinical relevance Mastitis Less than 200 ml daily (24 hours) production of breast milk on day 1 A positive pregnancy test at screening</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>August 2014</verification_date>
</DOC>